Joseph P. McEvoy, MD

  • 32Articles
  • 153.5KReads
  • 1997–2021Active
  • 87Collaborators
  • 278Citations

About

Joseph P. McEvoy, MD, is affiliated with the Department of Psychiatry and Health Behavior at the Medical College of Georgia, Augusta University, Augusta, Georgia. He has contributed to 32 articles published between 1997 and 2021 in Psychiatrist.com, focusing on topics such as schizophrenia, tardive dyskinesia, neurology, depression, movement disorders, bipolar disorder, and suicide. His frequent co-authors include Jeffrey A. Lieberman, Leslie Citrome, Jean-Pierre Lindenmayer, Stephen R. Marder, and T. Scott Stroup.

Publications

JCP
Original Research

Insomnia and Suicidality in CATIE

March 23, 2021

Insomnia is common in schizophrenia, but how does it affect suicidality and symptoms in these patients? This analysis of CATIE data provides answers.
, ,
JCP
Webcast

TD Evaluation and Patient Education

March 9, 2021

In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia, how to observe patients (whether in person or via telemedicine), and how to educate patients and families...
,
JCP
Educational Activity

Measuring Tardive Dyskinesia Improvement

November 3, 2020

Measurement-based care (MBC) has been found to be effective in patients with psychiatric conditions. In this CME activity, learn how Dr Joseph McEvoy employs MBC for patients with tardive...
JCP
Educational Activity

Treatment of Tardive Dyskinesia

September 29, 2020

Read an article on how to reduce Tardive dyskinesia (TD) symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
JCP
Academic Highlights

Identifying and Treating Tardive Dyskinesia

January 28, 2020

Review highlights from 2 experts' presentations on identifying and treating tardive dyskinesia. Quotes from actual patients illustrate the embarrassment that they feel and show why even mild movements should...
,
JCP
Consensus Statement

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
Educational Activity

FDA-Approved TD Medications

December 17, 2019

Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
JCP
Educational Activity

Psychosocial Implications of Tardive Dyskinesia

December 3, 2019

How does tardive dyskinesia affect patients' work and relationships? Should TD be treated even if patients lack insight into its presence? Dr Joseph McEvoy considers these questions and more...
JCP
Original Research

Valbenazine for Tardive Dyskinesia: Results From the KINECT 3 Study

December 18, 2018

Could valbenazine help your patients who experience antipsychotic-induced abnormal movements? This follow-up analysis of a phase 3 study provides further insights into the efficacy of valbenazine for tardive dyskinesia...
, , , et al
JCP
Original Research

Heterogeneity of Treatment Effects of LAI Antipsychotics

November 27, 2018

Which subgroups of patients with schizophrenia or schizoaffective disorder may be prone to treatment failure? Is it men or women, old or young, or are more factors involved? Researchers...
, , , et al
JCP
Educational Activity

Evidence-Based Strategies for Managing Tardive Dyskinesia

February 21, 2018

Do you know how to manage tardive dyskinesia symptoms? In this Case and Comment activity, consider the case of John, a 25-year-old project manager diagnosed with bipolar disorder who...
JCP
Educational Activity

What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options

February 21, 2018

Do you know which of your patients are at risk for developing tardive dyskinesia? Watch this Webcast to learn about how to prevent tardive dyskinesia in your patients and...
,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe